JP2019526532A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526532A5
JP2019526532A5 JP2018567866A JP2018567866A JP2019526532A5 JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5 JP 2018567866 A JP2018567866 A JP 2018567866A JP 2018567866 A JP2018567866 A JP 2018567866A JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5
Authority
JP
Japan
Prior art keywords
weight
composition
amount ranging
amount
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567866A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051721B2 (ja
JP2019526532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039968 external-priority patent/WO2018005777A1/en
Publication of JP2019526532A publication Critical patent/JP2019526532A/ja
Publication of JP2019526532A5 publication Critical patent/JP2019526532A5/ja
Priority to JP2022056589A priority Critical patent/JP2022088568A/ja
Application granted granted Critical
Publication of JP7051721B2 publication Critical patent/JP7051721B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567866A 2016-06-30 2017-06-29 デポー製剤 Expired - Fee Related JP7051721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022056589A JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US62/356,613 2016-06-30
US201662440658P 2016-12-30 2016-12-30
US62/440,658 2016-12-30
PCT/US2017/039968 WO2018005777A1 (en) 2016-06-30 2017-06-29 Depot formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022056589A Division JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Publications (3)

Publication Number Publication Date
JP2019526532A JP2019526532A (ja) 2019-09-19
JP2019526532A5 true JP2019526532A5 (enExample) 2020-08-06
JP7051721B2 JP7051721B2 (ja) 2022-04-11

Family

ID=60786467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567866A Expired - Fee Related JP7051721B2 (ja) 2016-06-30 2017-06-29 デポー製剤
JP2022056589A Pending JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022056589A Pending JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Country Status (16)

Country Link
US (2) US10668011B2 (enExample)
EP (1) EP3478285A4 (enExample)
JP (2) JP7051721B2 (enExample)
KR (1) KR20190025635A (enExample)
CN (2) CN115645399A (enExample)
AU (2) AU2017290143A1 (enExample)
BR (1) BR112018077259A2 (enExample)
CA (1) CA2972296A1 (enExample)
GE (1) GEP20207204B (enExample)
IL (1) IL263714A (enExample)
MX (1) MX387477B (enExample)
PH (1) PH12018502615A1 (enExample)
SG (1) SG11201810618QA (enExample)
TW (1) TWI765898B (enExample)
UA (1) UA124768C2 (enExample)
WO (2) WO2018005777A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731853B (zh) * 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
TWI765898B (zh) 2016-06-30 2022-06-01 美商杜瑞克公司 儲積調製劑
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
EP3787611A4 (en) 2018-05-01 2022-03-09 Chibi, Inc. LIQUID DEPOT FOR NONINVASIVE DELAYED DELIVERY OF DRUGS TO THE EYE
CA3097926A1 (en) * 2018-05-01 2019-11-07 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
JP7752051B2 (ja) * 2019-05-24 2025-10-09 デクラ ベテリナリー プロダクツ リミテッド ライアビリティー カンパニー 長時間作用型注射用製剤およびその使用
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
WO1993012160A1 (fr) 1991-12-19 1993-06-24 Mitsui Toatsu Chemicals, Inc. Acide polyhydroxy carboxylique et son procede de production
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
WO1996039995A1 (en) * 1995-06-07 1996-12-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
ATE427760T1 (de) 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
US8501215B2 (en) 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
DE60325511D1 (de) 2002-11-06 2009-02-05 Alza Corp Depot-formulierungen mit verzögerter freisetzung
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP3103477A1 (en) * 2004-09-17 2016-12-14 Durect Corporation Sustained local anesthetic composition containing saib
CN101890167B (zh) 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006227116A1 (en) 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
ES2447516T3 (es) 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
WO2008143992A2 (en) 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
JP5737949B2 (ja) * 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
CA2812102A1 (en) * 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
TW201334791A (zh) 2011-11-23 2013-09-01 杜瑞克公司 輻射滅菌之可生物降解之藥物遞送組合物
KR20220044379A (ko) 2012-01-23 2022-04-07 알러간, 인코포레이티드 고화 디포-형성 주사가능 약물 제형에 현탁된 서방형 생분해성 또는 생체흡수성 미소구체 또는 미립자
JP2016512523A (ja) 2013-03-11 2016-04-28 デュレクト コーポレーション 高粘性液体キャリアを含む注射用制御放出組成物
US20160038479A1 (en) 2013-03-15 2016-02-11 Durect Corporation Compositions with Thixotropy and Enhanced Dissolution Reproducibility and Stability
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN105407896B (zh) 2013-05-24 2019-08-27 爱康生物科技有限公司 缓释的地塞米松在白内障手术后的炎症中的应用
CN107249570B (zh) 2014-11-21 2022-08-09 丹麦技术大学 用于局部药物释放的凝胶制剂
TWI731853B (zh) 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
WO2017002941A1 (ja) 2015-07-01 2017-01-05 参天製薬株式会社 クエン酸エステルを含有するデポ剤
TWI765898B (zh) 2016-06-30 2022-06-01 美商杜瑞克公司 儲積調製劑
CA3049543A1 (en) 2017-01-06 2018-07-12 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer

Similar Documents

Publication Publication Date Title
JP2019526532A5 (enExample)
AU764626B2 (en) Pharmaceutical formulations of taxanes
WO2020083971A3 (en) New anthelmintic compounds
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
JP2017527532A5 (enExample)
MX360638B (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
AR110270A1 (es) Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos
RU2014129268A (ru) Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
JP2018507252A5 (enExample)
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
FI3586825T3 (fi) Biohajoavat lääkeaineen annostelukoostumukset
WO2009111057A4 (en) Fulvestrant formulations
KR20180024010A (ko) 동결건조된 약제학적 조성물
WO2014118808A3 (en) Ticagrelor solid dispersion
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
RU2488384C2 (ru) Композиции для лечения неопластических заболеваний
JP2017525758A5 (enExample)
RU2016140272A (ru) Стабильные ветеринарные антигельминтные композиции
JP2013530931A5 (enExample)
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JP2011512362A5 (enExample)
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
CA2797779A1 (en) Adhesive slow-release formulations for the local administration of curcumin
HRP20211558T1 (hr) Formulacija
CN110234324A (zh) 含有柳氮磺胺吡啶和透明质酸的眼用组合物